{"entity":{"id":"nct06253130","kind":"trial","name":"A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors","aka":[],"tldr":"This study tests a PARP inhibitor; the registry reports that it is recruiting.","summary":"The registry lists NCT06253130 as recruiting, last updated 2026-06-15. Enrolment is 156 planned participants, an estimate. Interventions: IMP1734. Primary measures include Number of subjects with adverse events, treatment emergent adverse events or serious adverse events; Maxim Tolerated Dose or Recommended Dose for Expansion. No results are posted in the registry; this does not exclude separate publications.","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT06253130","url":"https://clinicaltrials.gov/study/NCT06253130"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":["parp"],"drugs":["imp1734"],"companies":["eikon-therapeutics","impact-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06253130","phase":"1/2","setting":"A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation, Dose-optimization, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PARP1 Selective Inhibitor, IMP1734, as Monotherapy in Patients With Advanced Solid Tumors","sponsor":"Eikon Therapeutics","participation":[{"nct":"NCT06253130","source":"https://clinicaltrials.gov/study/NCT06253130","fetchedAt":"2026-10-07T16:54:23.000Z","studySha256":"8adc7a4788a135e631cd20d480373be8bbddf562a91622b15740c7b42ca9c248","overallStatus":"RECRUITING","lastUpdatePosted":"2026-06-15","leadSponsor":"Eikon Therapeutics","collaboratorCount":1,"minimumAge":"18 Years","maximumAge":"89 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":156,"enrolmentType":"ESTIMATED","siteCount":57,"recruitingSiteCount":46,"countries":["Australia","Canada","China","Denmark","France","South Korea","Spain","United States"]}],"started":"2023-12-11","startedType":"actual","enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06253130/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"imp1734","kind":"drug","name":"IMP1734","route":"/drugs/imp1734/"}],"company":[{"id":"eikon-therapeutics","kind":"company","name":"Eikon Therapeutics","route":"/companies/eikon-therapeutics/"},{"id":"impact-therapeutics","kind":"company","name":"IMPACT Therapeutics","route":"/companies/impact-therapeutics/"}]}}